Related Experiment Videos
[Increased p-homocysteine--a risk factor for thrombosis]
1Center for haemofili og trombose, klinisk immunologisk afdeling, Arhus Universitetshospital, Skejby Sygehus.
Insights
Elevated homocysteine levels increase the risk of blood clots and premature arteriosclerosis. Supplementation with folic acid and vitamin B6 can normalize homocysteine and potentially reduce thrombosis risk.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Clinical Nutrition
Context:
- Homocysteine, an amino acid, is linked to various health conditions.
- Elevated homocysteine levels are observed with aging, in males, and due to genetic or nutritional factors.
- Renal failure also contributes to increased homocysteine.
Purpose:
- To review the role of homocysteine in thrombosis and arteriosclerosis.
- To explore the correlation between homocysteine and lifestyle factors.
- To discuss the impact of homocysteine on endothelial function and coagulation.
Summary:
- Homocysteine levels naturally rise with age and are higher in middle-aged men.
- Elevated homocysteine is a significant risk factor for arterial and venous thrombosis, and premature arteriosclerosis.
- Positive correlations exist with smoking, blood pressure, and cholesterol; negative correlation with physical activity.
Impact:
- Understanding homocysteine's role aids in assessing cardiovascular risk.
- Folic acid and vitamin B6 supplementation can normalize homocysteine levels.
- Further research is needed to confirm the reduction in thrombosis risk following homocysteine normalization.
Abstract:
In the healthy population P-homocysteine increases with age and the level is higher in men aged 30-60 years as compared to women of the same age group. Most often, elevated P-homocysteine is caused by genetic defects, vitamin deficiency (folic acid, B6- and B12-vitamin) or renal failure. Based on retrospective as well as prospective studies, it can be concluded that elevated P-homocysteine is a risk factor for arterial as well as venous thrombosis. Severely elevated P-homocysteine is capable of causing premature arteriosclerosis, whereas slightly elevated levels may also be involved. A slightly positive correlation has been found between P-homocysteine on one hand, and smoking, blood pressure and cholesterol on the other, whereas physical activity is slightly negatively correlated to P-homocysteine. Altered function of endothelial cells and coagulation has been demonstrated in relation to elevated P-homocysteine, but the pathogenetic mechanisms have not been fully elucidated. Usually, an elevated P-homocysteine is normalised by folic acid supplementation, although additional treatment with vitamin B6 may be required. Presumably, the risk of thrombosis is thereby reduced, but future controlled studies may reveal whether this holds true.